Micromet investors savor €695 million BiTE deal with Amgen
This article was originally published in Scrip
Executive Summary
Rockville, Maryland-based Micromet inked a research deal with biotech giant Amgen for BiTE antibodies against three undisclosed solid tumour targets in exchange for €10 million up front, with the potential for the smaller firm to earn as much as €695 million (US$973 million).